Project Grant R01CA309682
Award Date 7/6/26
Completion Date 6/30/31
Dollars Obligated $472K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
College Station, TX 77843, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $694,643 to the University of California, San Diego on May 7, 2026, for research targeting the Hippo-YAP/TEAD signaling network in head and neck squamous cell carcinoma (HNSCC). This five-year research initiative, scheduled for completion by April 30, 2031, falls under the Cancer Treatment Research program (CFDA 93.395), which supports the discovery, development, and clinical testing of improved...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $194,914 to the University of Texas Health Science Center at Houston under the Cancer Research Manpower program (CFDA 93.398) on September 15, 2025, with completion targeted for August 31, 2028. Under the direction of Dr. Xu, this project delivers research services focused on modeling enhancer hijacking in cancer through genome engineering and single-cell sequencing methodologies. The research aims...
- Federal Grant Award Summary The National Cancer Institute awarded University of Texas at Austin a $150,898 Project Grant under the Cancer Biology Research program (CFDA 93.396) on June 8, 2026, to identify and validate novel mediators of cell-cell fusion in triple negative breast cancer (TNBC). Over the two-year performance period (through May 30, 2028), the research will deliver a pooled CRISPR activation screen to discover genes that promote homotypic cell-cell fusion in TNBC cells, coupled...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas Health Science Center at San Antonio a $609,846 Project Grant under CFDA 93.395 (Cancer Treatment Research) effective April 1, 2026 through March 31, 2031, to develop novel therapeutic approaches targeting mucin-type O-glycosylation in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). The research addresses a critical clinical gap: while EGFR tyrosine kinase...
- Federal Project Grant Award Summary The University of Texas Health Science Center at Houston received a $388,546 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. The award funds fundamental research investigating the role of chromosome 3q (3q)-amplified genes in non-small cell lung cancer (NSCLC) progression, specifically targeting the Golgi secretory pathway. The research focuses on how two...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a $401,115 Project Grant to the University of Texas Health Science Center at Houston for a two-year research initiative spanning August 1, 2026, through July 31, 2028. The award supports fundamental research investigating the molecular mechanisms by which hepatic Sirtuin 3 (SIRT3) regulates the progression from metabolic dysfunction-associated steatohepatitis (MASH)...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...
- Federal Grant Award Summary The National Cancer Institute awarded MD Anderson Cancer Center a $653,967 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective March 16, 2026, through February 28, 2031. This research initiative investigates the mechanistic basis and therapeutic strategies for PPP2R1A (Protein Phosphatase 2A, catalytic A subunit isoform) mutations in gynecological cancers, particularly uterine serous endometrial carcinoma and ovarian clear cell carcinoma....
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Arkansas for Medical Sciences a $628,980 Project Grant effective May 1, 2026, through April 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). The award supports research investigating the glycogen synthase kinase 3B (GSK3B)-53BP1 axis as a mechanism to enhance immune control of head and neck squamous cell carcinoma (HNSCC) and overcome T cell exhaustion (TEX), a primary limitation...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under its Cancer Treatment Research program (CFDA 93.395), awarded the University of Texas at Austin $668,878 on April 3, 2026, to develop novel antibody-drug conjugate (ADC) therapeutics targeting CD44 variant 9 (CD44V9) for treatment-resistant breast cancer. The five-year project, scheduled for completion on March 31, 2031, focuses on creating conditionally-active antibodies engineered to enhance tumor selectivity while...